Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.

Breast · 2020 · PMC7567051 · PMID 33065342

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

This resulted in a numerical trend in favor of ribociclib in TTD ≥10% in global HRQOL (HR = 0.81 [95% CI, 0.62–1.1]).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.